News

Gland Pharma trades higher on the BSE Gland Pharma is currently trading at Rs. 1587.75, up by 6.40 points or 0.40% from its previous closing of Rs. 1581.35 on the BSE. The scrip opened at Rs. 1590.05 and has touched a high and low of Rs. 1627.45 and Rs. 1585.55 respectively. So far 18174 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2606.00 on 02-Sep-2022 and a 52 week low of Rs. 861.50 on 22-May-2023. Last one week high and low of the scrip stood...
Gland Pharma trades higher on the BSE
Gland Pharma trades higher on the BSE
Source: Accord Fintech
24/08/2023 12:20:25 PM
India's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition Indian generic injectables maker Gland Pharma Ltd reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi. The Hyderabad-based company, which draws the bulk of its revenue from the United States, Europe, Canada, Australia and New Zealand, said revenue jumped to 12.09 billion Indian rupees ($146.13 million) from 8.57 billion rupees. The company said 37% of the total revenue came from its acquisition of Cenexi in January. Reve...
India's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition
India's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition
Source: Reuters
7/08/2023 7:33:59 PM
India's Gland Pharma reports lower Q4 profit on soft demand BENGALURU - Indian generic injectables maker Gland Pharma Ltd reported a 56% decline in fourth-quarter profit on Thursday, hurt by soft demand in its key operating markets. The company, majority of which is owned by China's Shanghai Fosun Pharmaceutical Group Co, said its consolidated profit before exceptional items and tax fell to 1.68 billion rupees ($20.54 million) for the quarter ended March 31, from 3.80 billion rupees a year earlier. Gland Pharma said it had a one-off expense ...
India's Gland Pharma reports lower Q4 profit on soft demand
India's Gland Pharma reports lower Q4 profit on soft demand
Source: Reuters
18/05/2023 8:15:27 PM
India's Mankind Pharma soars 32% in rare successful market debut BENGALURU  -Shares of India's Mankind Pharma Ltd ended with gains of 31.7% in their trading debut on Tuesday, valuing the maker of Manforce condoms at 569.76 billion rupees ($6.97 billion) in a rare instance of a successful domestic public listing this year. Mankind's 43.26 billion rupees initial public offering (IPO) ranks as India's biggest so far in 2023, and the third-biggest ever. It is also the biggest among Indian pharma companies since Gland Pharma Ltd went public ...
India's Mankind Pharma soars 32% in rare successful market debut
India's Mankind Pharma soars 32% in rare successful market debut
Source: Reuters
9/05/2023 7:44:53 PM
China`s Fosun drops plan to sell stake in Indian drugmaker Gland Pharma China's Shanghai Fosun Pharmaceutical Group Co Ltd has withdrawn plans to sell stake in Indian drugmaker Gland Pharma Ltd, ET Now tweeted on Wednesday, citing sources. Fosun Pharma holds a 57.86% stake in the Indian company. Both Fosun Pharma and Gland Pharma did not immediately respond to Reuters' requests for comment. Shares of Gland Pharma were up 0.8% at 1,360 rupees as of 9:50 a.m. IST. They have plunged 28% since November end, when Bloomberg News had reported, citing sourc...
China`s Fosun drops plan to sell stake in Indian drugmaker Gland Pharma
China`s Fosun drops plan to sell stake in Indian drugmaker Gland Pharma
Source: Reuters
26/04/2023 10:17:55 AM
Gland Pharma to invest Rs 400 cr in Hyderabad`s Genome Valley  Gland Pharma on Monday announced that it will invest over Rs 400 crore in Hyderabad's Genome Valley to add capabilities to their existing facility to manufacture biologicals, biosimilar, antibodies and recombinant insulin. The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February...
Gland Pharma to invest Rs 400 cr in Hyderabad`s Genome Valley
Gland Pharma to invest Rs 400 cr in Hyderabad`s Genome Valley
Source: IANS
21/02/2023 10:21:37 AM
Gland Pharma shines despite reporting 15% fall in Q3 consolidated net profit Gland Pharma is currently trading at Rs. 1424.30, up by 67.30 points or 4.96% from its previous closing of Rs. 1357.00 on the BSE. The scrip opened at Rs. 1350.05 and has touched a high and low of Rs. 1431.45 and Rs. 1350.05 respectively. So far 33210 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 3599.00 on 07-Feb-2022 and a 52 week low of Rs. 1309.00 on 24-Jan-2023. Last one week high and low of the scrip sto...
Gland Pharma shines despite reporting 15% fall in Q3 consolidated net profit
Gland Pharma shines despite reporting 15% fall in Q3 consolidated net profit
Source: Accord Fintech
25/01/2023 10:58:58 AM
Buy Gland Pharma Ltd For Target Rs 1,720 - Yes Securities Long road to recovery Result Synopsis Gland reported a weak quarter on back of declines in US and ROW revenues YoY as lack of customer offtake, still lingering supply concern and company opting margin over market share led to revenue shortfall. Gross and EBIDTA margin improved QoQ as a fallout of preference for margin vs market share; albeit management commentary of volume share being intact for top products appears out of sync with apparent preference for margin. Gland outlined seve...
Buy Gland Pharma Ltd For Target Rs 1,720 - Yes Securities
Buy Gland Pharma Ltd For Target Rs 1,720 - Yes Securities
Source: Yes Securities Ltd
24/01/2023 12:31:30 PM
Gland Pharma trades higher on the BSE Gland Pharma is currently trading at Rs. 1584.50, up by 7.50 points or 0.48% from its previous closing of Rs. 1577.00 on the BSE. The scrip opened at Rs. 1577.05 and has touched a high and low of Rs. 1598.80 and Rs. 1566.05 respectively. So far 11868 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 4060.00 on 06-Jan-2022 and a 52 week low of Rs. 1553.80 on 29-Dec-2022. Last one week high and low of the scrip stoo...
Gland Pharma trades higher on the BSE
Gland Pharma trades higher on the BSE
Source: Accord Fintech
4/01/2023 2:31:13 PM
India's Gland Pharma to buy Cenexi for $124 million in Europe push Indian generic injectables maker Gland Pharma Ltd said on Tuesday it will buy privately held French pharmaceutical firm Cenexi for 120 million euros ($124.3 million) as it looks to expand its presence in European markets. Carved out from Roche Holding in 2004, Cenexi is a contract development and manufacturing company which makes sterile and injectable pharmaceutical products, with three manufacturing sites in France and one in Belgium. Most of Cenexi's revenue comes from Europe wit...
India's Gland Pharma to buy Cenexi for $124 million in Europe push
India's Gland Pharma to buy Cenexi for $124 million in Europe push
Source: Reuters
29/11/2022 2:28:51 PM
Buy Gland Pharma Ltd For Target Rs.3,000 - Motilal Oswal Financial Services India and ROW hurt earnings Work in progress for product pipeline/newer markets/streamlining operations * Gland Pharma (GLAND) delivered weak 1QFY23 result due to multiple headwinds such as supply constraints of certain ancillary materials, plant modification-led lower production and reduced scope of business for certain products in the Indian market. While syringe-related hurdle is addressed, GLAND is working towards resolving other ancillary materials’ availability. * We cut ...
Buy Gland Pharma Ltd For Target Rs.3,000 - Motilal Oswal Financial Services
Buy Gland Pharma Ltd For Target Rs.3,000 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
29/08/2022 1:29:44 PM
Key Stock News - IDBI Bank Ltd, ITC Ltd, UltraTech Cement Ltd, Gland Pharma Ltd, Adani Group - ARETE Securities Key News IDBI Bank's Q1 net rises 25% to Rs 756 cr as provisions, contingencies dip Private sector lender IDBI Bank’s net profit rose 25 per cent year on year (YoY) to Rs 756 crore in the quarter ended June (Q1FY23), on the back of a sharp fall in provisions and contingencies. The bank had posted a net profit of Rs 603 crore during the same period last year (Q1FY22). Sequentially, its net profit rose by 10 per cent from Rs 691 crore in Q4FY22.   Hotel business de-m...
Key Stock News - IDBI Bank Ltd, ITC Ltd, UltraTech Cement Ltd, Gland Pharma Ltd, Adani Group - ARETE Securities
Key Stock News - IDBI Bank Ltd, ITC Ltd, UltraTech Cement Ltd, Gland Pharma Ltd, Adani Group - ARETE Securities
Source: ARETE Securities Ltd
22/07/2022 9:10:00 AM
Buy Gland Pharma Ltd For Target Rs.3,060 - Yes Securities   A forgettable quarter; all eyes on revenue recovery Result Synopsis Company expects rest of the fiscal to show improvement in growth of high teens over last year. We note that so far demand is holding up well as volumes in several key molecules is up sharply YoY even as impact of price erosion is fairly small at 1% for Gland for a say 10% decline at the front end. US business does appear to have bottomed out with 6% QoQ growth and with most of the syringe shortages taken care ...
Buy Gland Pharma Ltd For Target Rs.3,060 - Yes Securities
Buy Gland Pharma Ltd For Target Rs.3,060 - Yes Securities
Source: Yes Securities Ltd
21/07/2022 11:39:29 AM
Buy Gland Pharma Ltd For Target Rs. 3,700 - Motilal Oswal Multiple levers at play; valuations attractive * After delivering 27% earnings CAGR over FY17-22, GLAND is well-placed to sustain its earnings growth momentum over the next three-to-five years * It has been enhancing its offerings by adding complex products to its portfolio, scaling the product at the global level, expanding capacity to aid manufacturing, as well as increased backward integration. * While constraints on availability of certain materials may hinder performance ov...
Buy Gland Pharma Ltd For Target Rs. 3,700 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs. 3,700 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
27/06/2022 11:42:04 AM
Buy Gland Pharma Ltd For Target Rs.4,040 - Motilal Oswal Well-placed to gain from the drug shortages in the US Compliance/manufacturing scale-up offers heads-up to GLAND GLAND has 11 injectable products in the USFDA shortage list, which have combined sales of ~USD400m over the past 12-months. The overall number of drugs under shortage in the US has declined to a 15-year low at present. However, the number of injectables facing a shortage is at its 20- year average, but is at a record high as a percentage of total drug shortages. Among t...
Buy Gland Pharma Ltd For Target Rs.4,040 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs.4,040 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
20/04/2022 10:29:00 AM
Buy Gland Pharma Ltd For Target Rs.4,240 - Motilal Oswal Earnings growth momentum in sustainable mode On track to build complex product pipeline * Gland Pharma (GLAND) delivered a slight miss on 3QFY22 earnings. Overall, 3QFY22 performance was driven by the India/ROW market. GLAND is on track to build its product pipeline as well as invest in manufacturing infrastructure in the complex categories of Peptides / Long-acting Injectables / Suspensions / Hormonal Products. .* We lower our EPS estimate by 5% for FY22/FY23, largely to factor...
Buy Gland Pharma Ltd For Target Rs.4,240 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs.4,240 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
5/02/2022 9:24:29 AM
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities Growth outlook intact Our view Gland clocked yet another healthy topline quarter with US growth at 23% YoY. Key products like Micafungin, Ertapenem & Enoxaparin family drove growth during the quarter. We expect ramp up in Enoxaparin contract to support sustained momentum from April onwards while medium term outlook is bolstered by the 4 complex filings – 3 hormones & 1 peptide products – with cumulative market size of ~US$1bn (no generic yet in each) which would impr...
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Source: Yes Securities Ltd
25/01/2022 9:21:38 AM
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities An evolving injectable franchise * A robust revenue performance allays any concerns on growth with a strong follow up likely in Q3 as key products like Ertapenem and Enoxaparin deliver US growth. Cash generation to improve in H2 as receivables days to normalize * Faster growth in ROW markets to improve utilization of newly commissioned facilities and lines which was a constraint earlier; expect robust 30-35% rise in ROW sales over next 2-3 years as Gland leverages old registrations of U...
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Source: Yes Securities Ltd
11/01/2022 10:47:51 AM
Gland Pharma jumps despite weakness over Dalal Street Gland Pharma is currently trading at Rs. 3737.00, up by 92.20 points or 2.53% from its previous closing of Rs. 3644.80 on the BSE. The scrip opened at Rs. 3600.00 and has touched a high and low of Rs. 3760.00 and Rs. 3535.60 respectively. So far 4171 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 4350.00 on 12-Aug-2021 and a 52 week low of Rs. 2051.00 on 02-Feb-2021. Last one week high and low of the scrip stoo...
Gland Pharma jumps despite weakness over Dalal Street
Gland Pharma jumps despite weakness over Dalal Street
Source: Accord Fintech
20/12/2021 1:40:16 PM
Gland Pharma rises on receiving USFDA’s tentative approval for Cangrelor for Injection Gland Pharma is currently trading at Rs. 3585.55, up by 55.25 points or 1.57% from its previous closing of Rs. 3530.30 on the BSE. The scrip opened at Rs. 3522.40 and has touched a high and low of Rs. 3613.90 and Rs. 3522.00 respectively. So far 1033 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 4350.00 on 12-Aug-2021 and a 52 week low of Rs. 2050.00 on 16-Dec-2020. Last one week high and low of the scrip stoo...
Gland Pharma rises on receiving USFDA’s tentative approval for Cangrelor for Injection
Gland Pharma rises on receiving USFDA’s tentative approval for Cangrelor for Injection
Source: Accord Fintech
9/12/2021 9:49:08 AM
Buy Gland Pharma Ltd For Target Rs.5,000 - Emkay Global NDR takeaways: The ‘flywheel effect’ in motion * We hosted Gland Pharma management for a two-day non-deal roadshow in Mumbai to meet investors. Management commentary boosted our confidence in its unique business model, which is expected to benefit from increasing competition in generic injectables. * While the company steadily increases its portfolio offerings to existing customers such as Apotex, Fresenius Kabi and Pfizer (Hospira), it is also gaining traction with recent e...
Buy Gland Pharma Ltd For Target Rs.5,000 - Emkay Global
Buy Gland Pharma Ltd For Target Rs.5,000 - Emkay Global
Source: Emkay Global Financial Services Ltd
1/12/2021 11:23:07 AM
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities Revenue traction intact; BUY stays Our view Gland Pharma clocked yet another strong revenue quarter at 30% growth with US sales up a strong 20% yoy – in line with our expectation as outlined post Q1 FY22 numbers. Miss on gross margin is more a function of the mix rather than a direct fallout of higher input costs; albeit, we highlight strong operating leverage which restricted EBIDTA margin decline to ~100bps yoy. A robust revenue performance allays any concerns on growth with ...
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Buy Gland Pharma Ltd For Target Rs.4,500 - Yes Securities
Source: Yes Securities Ltd
26/10/2021 11:33:51 AM
Quote on Gland Pharma reported Q2FY22 numbers in line with market expectation By Mr. Yash Gupta, Angel One Ltd Below is quote on Gland Pharma reported Q2FY22 numbers in line with market expectation by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Gland Pharma Limited reported revenue from operation at ₹1,080 crores up by 30%, YoY ₹831.5 crores in Q2FY21, Rest of the world market has done well for the company up by 59% at ₹232.2 crores while Domestic market up by 19% at ₹183.5 crores. Company reported EBITDA margins of 38% up by 100 bps and EBITDA ...
Quote on Gland Pharma reported Q2FY22 numbers in line with market expectation By Mr. Yash Gupta, Angel One Ltd
Quote on Gland Pharma reported Q2FY22 numbers in line with market expectation By Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
25/10/2021 4:38:32 PM
Future-ready CDMO player with eyes on the Biosimilar market By Mr. Srinivas Sadu, MD and CEO, Gland Pharma, - Motilal Oswal Below are Views On Future-ready CDMO player with eyes on the Biosimilar market By Mr. Srinivas Sadu, MD and CEO, Gland Pharma, - Motilal Oswal What makes GLAND stand out from among the pack? Injectables have a higher entry barrier because of quality requirements and capex involved in setting up new facilities. Profitability in the business depends on throughput/yield from these facilities and consistent compliance. GLAND’s B2B business model ensures supply to a higher number ...
Future-ready CDMO player with eyes on the Biosimilar market By Mr. Srinivas Sadu, MD and CEO, Gland Pharma, - Motilal Oswal
Future-ready CDMO player with eyes on the Biosimilar market By Mr. Srinivas Sadu, MD and CEO, Gland Pharma, - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
9/09/2021 11:29:26 AM
Buy Gland Pharma Ltd For Target Rs.4,630 - Motilal Oswal Expanding niche portfolio/reach * Its core markets (US, Europe, Canada, and Australia) are expected to perform on the back of volume growth and new launches. * India and RoW markets are gaining traction, with additional capacities and geographic expansion. * China and Vaccine/Biologics are the new levers of growth in the existing business. * We expect 35% earnings CAGR over FY21-23E, led by 18%/44%/48% sales CAGR in its core markets/India/RoW and a 40bp margin expansion. We value ...
Buy Gland Pharma Ltd For Target Rs.4,630 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs.4,630 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
4/09/2021 10:34:13 AM
Buy Gland Pharma Ltd For Target Rs. 4,460 - Motilal Oswal Complex products/newer markets to fortify growth pace Progressing well on scaling up manufacturing of the vaccine * GLAND’s 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification. * We raise our FY22E/FY23E EPS estimate b...
Buy Gland Pharma Ltd For Target Rs. 4,460 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs. 4,460 - Motilal Oswal
Source: Motilal Oswal Financial Services
30/07/2021 10:24:41 AM
Quote on Gland pharma reported a good set of numbers for Q1FY22 by Mr. Yash Gupta, Angel Broking Ltd Below is quote on Gland pharma reported a good set of numbers for Q1FY22 by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd    Gland pharma reported a good set of numbers for Q1FY22 Gland pharma limited reported revenue from operation at ₹1153 crores up by 31% as compared to ₹884.2 crores in Q1FY21. Companies core market has reported revenue growth of 16% YoY as strong performance in existing products as well as new products launch. ...
Quote on Gland pharma reported a good set of numbers for Q1FY22 by Mr. Yash Gupta, Angel Broking Ltd
Quote on Gland pharma reported a good set of numbers for Q1FY22 by Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
22/07/2021 12:10:25 PM
Buy Gland Pharma Ltd For Target Rs. 4,500 - Yes Securities Our view A 30% revenue growth quarter should uniformly boost confidence and bolsters our belief of a sustainable revenue growth phase. While we would have ideally liked a more US driven beat in Q1, reckon US should rebound in subsequent quarters to 18‐20% growth. Call commentary is in sync with our thesis that even if ROW markets grow faster (which they will), overall margin trajectory should not inch lower. Reason being operating leverage would offset presumably reduced gross margin from ...
Buy Gland Pharma Ltd For Target Rs. 4,500 - Yes Securities
Buy Gland Pharma Ltd For Target Rs. 4,500 - Yes Securities
Source: Yes Securities
22/07/2021 11:52:10 AM
Key News - Bharti Airtel Ltd, Ceat Ltd, Jubilant Foodworks Ltd, Havells India Ltd, Gland Pharma Ltd by ARETE Securities Key News Bharti Airtel-Intel network deal to speed up 5G service roll-out Bharti Airtel on Wednesday announced a collaboration with Intel Corporation for 5G network development by leveraging virtual and open radio access network (O-RAN) technologies and making indigenous solutions. Airtel and other telecommunications (telecom) operators are conducting 5G trials in select cities across India. “The collaboration is part of Airtel’s 5G road map for India as it transforms its ne...
Key News - Bharti Airtel Ltd, Ceat Ltd, Jubilant Foodworks Ltd, Havells India Ltd, Gland Pharma Ltd by ARETE Securities
Key News - Bharti Airtel Ltd, Ceat Ltd, Jubilant Foodworks Ltd, Havells India Ltd, Gland Pharma Ltd by ARETE Securities
Source: ARETE Securities Ltd
22/07/2021 8:42:51 AM
Buy Gland Pharma Ltd For Target Rs.3,280 - Motilal Oswal Building multiple levers to sustain the growth momentum Margin surprise in 4QFY21 led by product mix and lower opex * GLAND delivered better than expected 4QFY21, led by a superior product mix and better operating leverage. It is scaling up its COVID-19 vaccine manufacturing as well as expanding its sterile injectable/API/Oncology facilities to cater to upcoming launches. * We raise our FY22E/FY23E EPS estimate by 5%/4% to factor in: a) strong traction in RoW markets, b) increased of...
Buy Gland Pharma Ltd For Target Rs.3,280 - Motilal Oswal
Buy Gland Pharma Ltd For Target Rs.3,280 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
12/06/2021 10:08:09 AM
Gland Pharma - 4QFY21 By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Gland Pharma - 4QFY21 by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd    Gland pharma reported a good set of numbers for the quarter Q4FY21.  Gland pharma limited reported total revenue from operations at ₹887 crores up by 40% YoY from ₹ 635 crores in Q4FY20. Export core market revenue up by 29% to ₹619.3 crores while domestic market has reported growth of 15...
Gland Pharma - 4QFY21 By Mr. Yash Gupta, Angel Broking Ltd
Gland Pharma - 4QFY21 By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
18/05/2021 11:31:57 AM
Buy Gland Pharma Ltd For Target Rs. 3,050 - Yes Securities Result Highlights * Revenues jumped ~40% YoY on the back of strong growth in core markets (US & Europe +29% YoY), India (+15% YoY) and ROW (+196% YoY). * In domestic market, Gland ramped up Remdesivir supply and maintained supplies of Enoxaparin   * Gross margin declined by 388bps YoY to 55.9% while EBITDA margin contraction restrained at 85bps YoY to 36.9%. Higher R&D too dampened margin   * R&D expenses at Rs304mn (vs. Rs173mn in Q4 FY20). * FY...
Buy Gland Pharma Ltd For Target Rs. 3,050 - Yes Securities
Buy Gland Pharma Ltd For Target Rs. 3,050 - Yes Securities
Source: Yes Securities Ltd
18/05/2021 11:11:18 AM
Key News - Colgate-Palmolive Ltd, Bharti Airtel Ltd, Orient Cement Ltd, Gland Pharma Ltd, Federal Bank, Tata Motors Ltd by ARETE Securities Key News Colgate-Palmolive India Q4 net profit jumps 54% to Rs 314.6 crore Consumer goods major Colgate-Palmolive India on Monday reported a 54.1 per cent increase in its net profit to Rs 314.6 crore in Q4 versus a year ago, helped by a low base and all-round growth across categories. Its net sales were up 20.2 per cent YoY to Rs 1,275.01 crore in Q4, versus Rs 1,062.35 crore in the year-ago period. Ram Raghavan, managing director at ColgatePalmolive (India), said the company continued ...
Key News - Colgate-Palmolive Ltd, Bharti Airtel Ltd, Orient Cement Ltd, Gland Pharma Ltd, Federal Bank, Tata Motors Ltd by ARETE Securities
Key News - Colgate-Palmolive Ltd, Bharti Airtel Ltd, Orient Cement Ltd, Gland Pharma Ltd, Federal Bank, Tata Motors Ltd by ARETE Securities
Source: ARETE Securities Ltd
18/05/2021 9:10:59 AM
LKP Spade, Weekly Pick - Buy Gland Pharma Limited For Target Rs.2960 - LKP Securities * Stock moving northwards in its standard pattern of breakout retest as we can see on charts. * Now again prices are moving up after touching its breakout zone and also prices are well trading above its rising trend line. * Nice volume also has been witnessed at the time retest. Buy GLAND PHARMA LTD @2785-2795 TGT 2960 Stop Loss Below Rs. 2640 CB​​​​​​​ Duration 1 Week     To Read Complete Report & Disclaimer Click Here &nbs...
LKP Spade, Weekly Pick - Buy Gland Pharma Limited For Target Rs.2960 - LKP Securities
LKP Spade, Weekly Pick - Buy Gland Pharma Limited For Target Rs.2960 - LKP Securities
Source: LKP Securities Ltd
3/05/2021 11:08:25 AM
Gland Pharma jumps on getting USFDA`s nod for generic Foscarnet Sodium Injection Gland Pharma is currently trading at Rs. 2725.80, up by 67.85 points or 2.55% from its previous closing of Rs. 2657.95 on the BSE. The scrip opened at Rs. 2713.00 and has touched a high and low of Rs. 2741.35 and Rs. 2704.10 respectively. So far 2250 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2879.00 on 20-Apr-2021 and a 52 week low of Rs. 1701.00 on 20-Nov-2020. Last one week high and low of the scrip stoo...
Gland Pharma jumps on getting USFDA`s nod for generic Foscarnet Sodium Injection
Gland Pharma jumps on getting USFDA`s nod for generic Foscarnet Sodium Injection
Source: Accord Fintech
23/04/2021 9:48:14 AM
India`s Gland Pharma to make up to 252 million Sputnik V vaccine doses BENGALURU - Gland Pharma Ltd said on Tuesday it had struck a deal with the Russian Direct Investment Fund (RDIF) to make up to 252 million doses of the Sputnik V COVID-19 vaccine, bringing India's total production of the shot to at least 352 million. Shares of Gland Pharma, which is backed by China-based Shanghai Fosun Pharmaceutical Group Co Ltd, surged as much as 9.5% to hit a record high of 2,783.85 rupees. India's Hetero already has a deal in place to produce over 100 millio...
India`s Gland Pharma to make up to 252 million Sputnik V vaccine doses
India`s Gland Pharma to make up to 252 million Sputnik V vaccine doses
Source: Reuters
16/03/2021 5:03:26 PM
India`s Gland Pharma jumps 23% in market debut BENGALURU  - Shares of India's Gland Pharma got off to a flying start in their market debut on Friday, rising as much as 23% and highlighting a strong appetite for drug stocks. The Hyderabad-based company opened at 1,710 rupees per share, after its stock was priced at 1,500 rupees in India's largest initial public offering by a drugmaker, giving it a market value of 279.21 billion rupees. Pharma stocks are on a tear this year, with the Nifty Pharma Index up nearly 44%, far ...
India`s Gland Pharma jumps 23% in market debut
India`s Gland Pharma jumps 23% in market debut
Source: IANS
20/11/2020 2:27:27 PM
Quote on Gland Pharma IPO By Yash Gupta, Angel Broking Below are Quote on Gland Pharma IPO By Mr. Yash Gupta- Equity Research Associate, Angel Broking Ltd “Gland Pharma IPO the biggest pharma IPO in India has only received 4% of subscription on day 1 of the IPO i.e 9th November 2020, Company IPO will be open for subscription from 9th November to 11th November 2020. IPO is receiving low interest from retail investors, company received 1943 crores from Anchor investor on Saturday. Company fixed a price band of 1490...
Quote on Gland Pharma IPO By Yash Gupta, Angel Broking
Quote on Gland Pharma IPO By Yash Gupta, Angel Broking
Source: Angel Broking Ltd
11/11/2020 11:33:52 AM
Gland Pharma announces launch of initial public offering Gland Pharma Ltd. has announced public offering of 43196968 shares at a price of Rs 1.00 each for Cash at a Premium of Rs 1,499.00 per share. The gross proceeds of the issue are expected to be Rs 6,47,954.52 lakhs. The company's initial public offer (IPO) will open on 09 November 2020 and is expected to close on 11 November 2020, subject to customary closing conditions. The price band of the issue has been fixed at Rs 1,490.00-1,500.00 per share. The IPO includes a fresh Issue of 43...
Gland Pharma announces launch of initial public offering
Gland Pharma announces launch of initial public offering
Source: Dion Global Solutions Ltd
5/11/2020 4:28:03 PM